| Literature DB >> 34603198 |
Mengni Li1, Rongping Fan1, Xuemin Peng1, Jiaojiao Huang1, Huajie Zou1, Xuefeng Yu1,2, Yan Yang1,2, Xiaoli Shi1,2, DeLin Ma1,2.
Abstract
Background: Previous studies showed altered angiopoietin-like protein-8 (ANGPTL-8) and resistin circulating levels in type 2 diabetes mellitus (T2DM). Whether or not the alteration in ANGPTL-8 and resistin level can be a predictive maker for increased diabetic nephropathy risk remains unclear. Aim: To Investigate the possible association of ANGPTL-8 and resistin with DN, and whether this association is affected by NAFLD status.Entities:
Keywords: ANGPTL-8; diabetic nephropathy; non-alcoholic fatty liver; predictive effect; resistin; type 2 diabetes mellitus
Mesh:
Substances:
Year: 2021 PMID: 34603198 PMCID: PMC8479106 DOI: 10.3389/fendo.2021.695750
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Anthropometric and biochemical characteristics of participants.
| Variables | Non-DN (n=159) | DN (n=119) | |
|---|---|---|---|
| Age (years) | 52.08 ± 13.20 | 55.31 ± 13.94 | 0.05 |
| Male (%) | 104 (65.4) | 77 (64.7) | 0.903 |
| BMI (kg/m2) | 24.87 ± 4.20 | 24.55 ± 3.77 | 0.427 |
| HbA1c (%) | 8.90 ± 2.42 | 9.39 ± 2.48 | 0.103 |
| FPG (mmol/L) | 8.27 ± 2.99 | 8.39 ± 3.15 | 0.749 |
| HOMA-IR | 5.21 (2.78,8.26) | 6.41 (3.44,11.11) | 0.051 |
| HOMA-β | 139.50(75.00,233.00) | 152.90(69.10,285.30) | 0.323 |
| Duration of diabetes (years) | 5.00 (1.00,11.00) | 6.00 (1.00,12.00) | 0.593 |
| TG(mmol/L) | 2.31 ± 3.06 | 2.33 ± 1.81 | 0.953 |
| TC (mmol/L) | 4.15 ± 1.23 | 4.13 ± 1.16 | 0.886 |
| LDL-C (mmol/L) | 2.48 ± 0.89 | 2.51 ± 0.93 | 0.806 |
| HDL-C (mmol/L) | 1.06 ± 0.29 | 1.01 ± 0.29 | 0.183 |
| AST (U/L) | 22.59 ± 15.74 | 28.14 ± 28.47 |
|
| ALT (U/L) | 30.02 ± 44.03 | 29.53 ± 34.03 | 0.920 |
| BUN (mmol/l) | 5.93 ± 1.87 | 7.20 ± 4.78 |
|
| Scr (μmol/L) | 67.58 ± 16.72 | 104.71 ± 59.70 |
|
| eGFR (mL/min/1.73 m2) | 100.95 ± 16.11 | 75.00 ± 31.10 |
|
| UACR (mg/mmol) | 9.53 ± 7.05 | 797.99 ± 1558.68 |
|
| hs-CRP(mmol/l) | 8.91 ± 25.42 | 29.67 ± 50.23 |
|
| Smoking (%) | 46 (28.9) | 93 (33.5) | 0.065 |
| Drinking (%) | 29 (18.4) | 18 (15.1) | 0.479 |
| Hypertension (%) | 68 (42.8) | 70(58.8) |
|
| NAFLD (%) | 57 (35.8%) | 34 (28.6%) | 0.201 |
Data are means ± SD or median (interquartile range).
BMI, body mass index; HbA1c, hemoglobin A1c; FPG, fasting plasma glucose concentration; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment of beta cell function; TG, triglyceride; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; AST, aspartate transaminase; ALT, aminotransferase activity; BUN, blood urea nitrogen; Scr, Serum Creatinine; eGFR, glomerular filtration rate; UACR, urine albumin/creatinine ratio; UAE, urinary albumin excretion; hs-CRP, hypersensitive C-reactive protein;NAFLD, nonalcoholic fatty liver disease.
P < 0.05 was considered statistically significant.
Bold: p < 0.05.
Figure 1ANGPTL8 and resistin levels in T2DM patients. (A), ANGPTL8 levels were significantly elevated in the DN group. (B), Resistin levels were higher in the DN group. ***p < 0.001 vs. non-DN group.
Correlations of ANGPTL8 and resistin with anthropometric parameters and biochemical indexes in all patients.
| Variables | ANGPTL8 | resistin | |||
|---|---|---|---|---|---|
|
|
| ||||
| Age (years) | 0.203 |
| 0.051 | 0.397 | |
| BMI (kg/m2) | -0.14 | 0.816 | -0.039 | 0.513 | |
| HbA1c | 0.069 | 0.250 | 0.059 | 0.325 | |
| FPG | 0.079 | 0.191 | 0.049 | 0.414 | |
| HOMA-IR | 0.079 | 0.189 | 0.079 | 0.188 | |
| HOMA-β | 0.006 | 0.922 | 0.022 | 0.720 | |
| Duration of diabetes | 0.068 | 0.259 | 0.031 | 0.610 | |
| TG (mmol/L) | -0.022 | 0.731 | 0.042 | 0.489 | |
| TC (mmol/L) | -0.085 | 0.165 | -0.093 | 0.129 | |
| LDL-C (mmol/L) | -0.087 | 0.162 | -0.040 | 0.521 | |
| HDL-C (mmol/L) | 0.015 | 0.807 | -0.107 | 0.087 | |
| AST (U/L) | 0.034 | 0.581 | -0.006 | 0.917 | |
| ALT (U/L) | -0.051 | 0.404 | -0.30 | 0.628 | |
| BUN (mmol/l) | -0.045 | 0.465 | 0.161 |
| |
| Scr (μmol/L) | 0.160 |
| 0.278 |
| |
| eGFR (mL/min/1.73 m2) | -0.195 |
| -0.289 |
| |
| UACR (mg/mmol) | 0.329 |
| 0.300 |
| |
| hs-CRP(mmol/l) | 0.171 |
| 0.245 |
| |
BMI, body mass index; HbA1c, hemoglobin A1c; FPG, fasting plasma glucose concentration; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment of beta cell function; TG, triglyceride; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; AST, aspartate transaminase; ALT, aminotransferase activity; BUN, blood urea nitrogen; Scr, Serum Creatinine; eGFR, glomerular filtration rate; UACR, urine albumin/creatinine ratio; UAE, urinary albumin excretion; hs-CRP, hypersensitive C-reactive protein.
Bold: p < 0.05.
Figure 2ANGPTL8 was positively associated with resistin in DN in non-NAFLD. (A), ANGPTL8 was positively associated with resistin in DN. (B), ANGPTL8 was positively associated with resistin in non-NAFLD, but not in NAFLD group. *p < 0.05 vs. non-DN group. **p < 0.01 vs. NAFLD group.
Logistic Regression Analysis of ANGPTL8 and resistin for diabetic nephropathy in all patients.
| Models | Variables | Diabetic nephropathy | |
|---|---|---|---|
| OR (95%CI) |
| ||
| Model 1 | ANGPTL8 | 2.306(1.418-3.749) |
|
| resistin | 2.476(1.496-4.098) |
| |
| Model 2 | ANGPTL8 | 2.179(1.324-3.587) |
|
| resistin | 2.449(1.474-4.068) |
| |
| Model 3 | ANGPTL8 | 2.095(1.253-3.502) |
|
| resistin | 2.499(1.484-4.208) |
| |
Model 1: unadjusted.
Model 2: adjusted for age, gender and BMI.
Model 3: adjusted for age, gender, BMI, smoking, drinking, HbA1c and duration of diabetes.
Bold: p < 0.05.
Figure 4ROC curves for the diagnostic accuracy of the ANTPTL8 and resistin for DN. (A), ROC curves of total population. (B), ROC curves in the non-NAFLD population.
Figure 3T2DM patients with DN had higher levels of ANGPTL8 and resistin In non-NAFLD population. (A), ANGPTL8 levels were elevated in non-NAFLD population. (B), Resistin levels were elevated in non-NAFLD population. ***p < 0.001 vs. NAFLD group. NS, non significance.
Logistic regression analysis of ANGPTL8 and resistin respectively for diabetic nephropathy in the non-NAFLD and NAFLD population.
| Models | Variables | Non-NAFLD | NAFLD | ||
|---|---|---|---|---|---|
| OR (95%CI) |
| OR (95%CI) |
| ||
| Model 1 | ANGPTL8 | 2.713 (1.494-4.926) |
| 1.742 (0.739-4.104) | 0.205 |
| resistin | 4.248 (2.260-7.987) |
| 0.720 (0.281-1.843) | 0.493 | |
| Model 2 | ANGPTL8 | 2.488 (1.352-4.579) |
| 1.856 (0.756-4.554) | 0.177 |
| resistin | 4.149 (2.192-7.855) |
| 0.739 (0.286-1.912) | 0.533 | |
| Model 3 | ANGPTL8 | 2.437 (1.296-4.579) |
| 2.667 (0.938-7.580) | 0.066 |
| resistin | 4.406 (2.275-8.533) |
| 0.758 (0.270-2.123) | 0.597 | |
Model 1: unadjusted.
Model 2: adjusted for age, gender and BMI.
Model 3: adjusted for age, gender, BMI, smoking, drinking, HbA1c and duration of diabetes.
Bold: p < 0.05.